• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
World J Gastroenterol. 2021 Nov 21;27(43):7497-7508. doi: 10.3748/wjg.v27.i43.7497.ABSTRACTNew hepatitis B virus (HBV) infections are decreasing owing to improved antiviral therapy and increased HBV vaccination worldwide; however, the number of HBV infections remains a major cause of liver carcinogenesis. HBV triggers cytotoxic immunity to eliminate HBV-infected cells. Therefore, the HBV pathophysiology changes in persistently infected individuals depending on host immune responses and HBV DNA proliferation state. To prevent liver cirrhosis and carcinogenesis caused by HBV, it is important to treat HBV infection at an earl...
Source: World Journal of Gastroenterology - December 10, 2021 Category: Gastroenterology Authors: Miwa Kawanaka Ken Nishino Hirofumi Kawamoto Ken Haruma Source Type: research

Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine resp...
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news

Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan
This study investigated anal HPV infections and cytological abnormalities among MSM with or without HIV infection. Anal swabs were obtained, and cytological results were examined. Hybrid capture-based methodology was used for hr-HPV genotyping. The exclusion criterion was a history of vaccination against HPV. 644 subjects participated, and the overall prevalence of hr-HPV was 59.7% (95% CI 54.7-62.3), HIV-infected had higher prevalence than HIV-uninfected (68.9% vs 40.6%) p < .001. Among hr-HPV-infected participants, 82.8% (312/377) were infected with at least one of 9 valent vaccine-covered hr-HPV genotypes. From regre...
Source: Anal Sci - September 29, 2021 Category: Chemistry Authors: Daisuke Shiojiri Daisuke Mizushima Misao Takano Koji Watanabe Naokatsu Ando Haruka Uemura Yasuaki Yanagawa Takahiro Aoki Junko Tanuma Kunihisa Tsukada Katsuji Teruya Yoshimi Kikuchi Hiroyuki Gatanaga Shinichi Oka Source Type: research

Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence
Vaccine. 2021 Sep 7:S0264-410X(21)01145-2. doi: 10.1016/j.vaccine.2021.08.085. Online ahead of print.ABSTRACTVaccine hesitancy is a growing concern in global public health, and illustrates serious problems arising from loss of social trust. Japan is experiencing a human papillomavirus (HPV) vaccine crisis that started with a rapid decline in the vaccination rate in 2013 from approximately 70% to less than 1% and lasting for 7 years. We analyze Japan's case of vaccine hesitancy for HPV vaccine, using a framework for examining barriers to access and use of health technologies according to four categories: architecture, avail...
Source: Vaccine - September 11, 2021 Category: Allergy & Immunology Authors: Keiko Kunitoki Masafumi Funato Makiko Mitsunami Takahiro Kinoshita Michael R Reich Source Type: research

Fight Aging! Newsletter, August 30th 2021
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out mo...
Source: Fight Aging! - August 29, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Pages: 1  2  3  4  5  6  7  8  9